Related references
Note: Only part of the references are listed.Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints
Manish R. Sharma et al.
CLINICAL CANCER RESEARCH (2012)
Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Wilfred D. Stein et al.
CLINICAL CANCER RESEARCH (2012)
Simulations Using a Drug-Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non-Small-Cell Lung Cancer
L. Claret et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Designing phase II trials in cancer: a systematic review and guidance
S. R. Brown et al.
BRITISH JOURNAL OF CANCER (2011)
Clinical trials in the era of personalized oncology
Michael L. Maitland et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy
Daniel Y. C. Heng et al.
CANCER (2011)
More Randomization in Phase II Trials: Necessary but not Sufficient
Lawrence Rubinstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Randomized Phase II Trials: A Long-term Investment With Promising Returns
Manish R. Sharma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology
Michael L. Maitland et al.
CLINICAL CANCER RESEARCH (2010)
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Lesley Seymour et al.
CLINICAL CANCER RESEARCH (2010)
Randomized Phase II Trials: Inevitable or Inadvisable?
Hui K. Gan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase II Trials Time for a New Era in Clinical Trial Design
Sumithra J. Mandrekar et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Other Paradigms: Better Treatments Are Identified by Better Trials The Value of Randomized Phase II Studies
Manish R. Sharma et al.
CANCER JOURNAL (2009)
Novel Designs and End Points for Phase II Clinical Trials
Alex A. Adjei et al.
CLINICAL CANCER RESEARCH (2009)
Randomized Phase II Designs
Larry Rubinstein et al.
CLINICAL CANCER RESEARCH (2009)
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine plus carboplatin in non-small cell lung cancer patients
Lai-San Tham et al.
CLINICAL CANCER RESEARCH (2008)
Extensions to the Visual Predictive Check to facilitate model performance evaluation
Teun M. Post et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage
Wilfred D. Stein et al.
ONCOLOGIST (2008)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Economics of new oncology drug development
Joseph A. DiMasi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The phase III trial in the era of targeted therapy: Unraveling the go or no go decision
TG Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check
Y Yano et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
